BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 9466277)

  • 41. Sustained molecular remission in a patient with CML in blastic crisis receiving dose-reduced hematopoietic stem-cell transplantation followed by early withdrawal of cyclosporine and prophylactic use of interferon-alpha.
    Hamaki T; Kami M; Momomura S; Mineishi S; Kusumi E; Kanda Y; Ueyama J; Miyakoshi S; Morinaga S; Takaue Y; Mutou Y
    Am J Hematol; 2002 Nov; 71(3):196-9. PubMed ID: 12410575
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Mackinnon S; Barnett L; Heller G
    Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
    Hambach L; Eder M; Dammann E; Battmer K; Stucki A; Heil G; Ganser A; Hertenstein B
    Bone Marrow Transplant; 2001 Oct; 28(7):705-7. PubMed ID: 11704795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation.
    Santini V; Zoccolante A; Bosi A; Guidi S; Saccardi R; Vannucchi AM; Martinazzo G; Bernabei PA; Ferrini PR
    Haematologica; 1996; 81(3):201-7. PubMed ID: 8767524
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Importance of mixed chimerism to predict relapse in persistently BCR/ABL positive long survivors after allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Román J; Martín C; Torres A; García A; Andrés P; García MJ; Baiget M
    Leuk Lymphoma; 1998 Feb; 28(5-6):541-50. PubMed ID: 9613984
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
    Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
    Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning.
    Lange T; Deininger M; Brand R; Hegenbart U; Al-Ali H; Krahl R; Poenisch W; Uharek L; Leiblein S; Gentilini C; Petersdorf E; Storb RF; Niederwieser D
    Leukemia; 2004 Sep; 18(9):1468-75. PubMed ID: 15241437
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Dazzi F; Szydlo RM; Cross NC; Craddock C; Kaeda J; Kanfer E; Cwynarski K; Olavarria E; Yong A; Apperley JF; Goldman JM
    Blood; 2000 Oct; 96(8):2712-6. PubMed ID: 11023502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.
    Niederle N; Kloke O; Wandl UB; Becher R; Moritz T; Opalka B
    Leuk Lymphoma; 1993 Jan; 9(1-2):111-9. PubMed ID: 8477190
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
    Hertenstein B; Wiesneth M; Novotny J; Bunjes D; Stefanic M; Heinze B; Hübner G; Heimpel H; Arnold R
    Transplantation; 1993 Nov; 56(5):1114-8. PubMed ID: 8249110
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J; Alvarez MA; Torres A
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction of molecular remission by donor peripheral blood leukocyte therapy in patients relapsing with extramedullary blastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation.
    Bashey A; Shepherd S; Frankel W; Wang-Rodriguez J; Cahill T; Chamberlain M; Mason JR; Ho AD; Corringham RE
    Oncol Rep; 1998; 5(1):281-5. PubMed ID: 9458334
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Samuel S; Kapelushnik J; Brautbar C; Or R
    Blood; 1996 Mar; 87(6):2195-204. PubMed ID: 8630379
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow.
    Elmaagacli AH; Beelen DW; Opalka B; Seeber S; Schaefer UW
    Blood; 1999 Jul; 94(2):384-9. PubMed ID: 10397704
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Successful treatment with donor leukocyte transfusion followed by interferon-alpha in a patient with relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation].
    Maeda A; Yamamoto K; Kotone Y; Yamashita K; Yoshinaga N; Hirata H; Asagoe K; Nohgawa M; Takahashi A; Ohno H; Tashima M; Sasada M
    Rinsho Ketsueki; 1998 Jun; 39(6):442-6. PubMed ID: 9695673
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.
    Koren-Michowitz M; Shimoni A; Daraio F; Crasto F; Lorenzatti R; Volchek Y; Amariglio N; Gottardi E; Saglio G; Nagler A
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1852-5. PubMed ID: 26151304
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Bone marrow transplantation in chronic myeloid leukemia].
    Milone JH; Bordone J; Etchegoyen O; Napal J; Prates MV; Morales VH
    Medicina (B Aires); 1999; 59(1):1-10. PubMed ID: 10349111
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.
    Sawyers CL; Timson L; Kawasaki ES; Clark SS; Witte ON; Champlin R
    Proc Natl Acad Sci U S A; 1990 Jan; 87(2):563-7. PubMed ID: 2405384
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Leukemic burden in subpopulations of CD34+ cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic myeloid leukemia.
    Van den Berg D; Wessman M; Murray L; Tong J; Chen B; Chen S; Simonetti D; King J; Yamasaki G; DiGiusto R; Gearing D; Reading C
    Blood; 1996 May; 87(10):4348-57. PubMed ID: 8639795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.